Parnell Pharmaceuticals Holdings Ltd
PARNF · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.9% | 3.5% | 9.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 56.4% | 58.4% | 60% | 58.5% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 17.6% | 14.1% | 8.3% | 19.8% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -4.2% | -50.2% | -24.8% | 0.5% |
| EPS Diluted | -0.049 | -0.81 | -0.4 | 0.007 |
| % Growth | 94% | -102.5% | -5,680.5% | – |
| Operating Cash Flow | $0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | -$0 |